Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
addressed, admitted, AHA, attributed, authoritative, billable, billed, busiest, caption, Carlo, carryforward, CEA, cloud, contemplated, customary, Defense, disaggregated, dissolve, entirety, epithelium, expedient, GAAP, Hermann, hosting, hyperinflammatory, installment, instrument, iPSC, kidney, largest, logistical, LTIP, markup, Memorial, Monte, month, nominate, nominated, nominee, noncancellable, Nonemployee, nonimmunogenic, nonrecurring, opthalmology, outdated, pigment, plasminogen, preceding, precluded, predominant, prequalified, prophylactic, proportionate, reassessed, redundant, remeasurement, retinal, ROFN, SanBio, satisfaction, satisfied, Simplification, simulation, software, standstill, superseded, thrombectomy, ticker, tranche, transformation, unbilled, unconditional, unsatisfied, usage, UTHealth
Removed:
added, allocate, April, arterial, byCirculation, certificate, Codification, competent, Conference, CTA, decisive, deep, determinable, dynamically, ECS, excellence, excluding, focusing, huge, IBD, incorporation, Innovate, interparty, Kingdom, KUL, label, legally, link, marked, maximum, methodically, Neuroinflammation, obesity, observability, omitted, oncology, paper, participated, principle, proof, reclassification, reliable, remove, responding, retrospectively, SAB, servedex, shared, soar, substantive, successor, vision, web
Filing tables
Filing exhibits
Related press release
Associated ATHXQ transcripts
ATHXQ similar filings
Filing view
External links
EXHIBIT 10.34
SUMMARY OF ATHERSYS, INC.
2019 CASH BONUS INCENTIVE PLAN
On January 11, 2019, the Board of Directors of Athersys, Inc. (the “Company”), based upon the recommendation of the Compensation Committee of the Board of Directors of the Company, approved a cash bonus incentive plan (the “Plan”) for the year ended December 31, 2019 for the named executive officers of the Company. The Plan provides that each participant is eligible to earn a bonus during the award term of January 1, 2019 through December 31, 2019. The Plan provides for the following target bonus percentages of the named executive officer’s salary during the award term, weighted as set forth below on the achievement of specified corporate goals, with the remainder based on individual/functional performance. The corporate goals include advancing the Company’s clinical programs for MultiStem, executing against the established operating plan and capital acquisition objectives, and advancement of strategic partnership and program activities. There is no formally adopted plan document for the Plan.
| Title | Target Bonus | Weighting on Corporate Goals | ||||
| Chief Executive Officer | 60 | % | 100 | % | ||
| President & Chief Operating Officer | 45 | % | 80 | % | ||
| Executive Vice President & Chief Scientific Officer | 45 | % | 80 | % | ||
| Senior Vice President of Finance | 35 | % | 60 | % | ||